Telmisartan/amlodipine/indapamide
| Combination of | |
|---|---|
| Telmisartan | angiotensin II receptor blocker |
| Amlodipine | dihydropyridine calcium channel blocker |
| Indapamide | thiazide-like diuretic |
| Clinical data | |
| Trade names | Widaplik |
| AHFS/Drugs.com | Widaplik |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| ATC code |
|
| Legal status | |
| Legal status | |
Telmisartan/amlodipine/indapamide, sold under the brand name Widaplik, is a fixed-dose combination medication used for the treatment of hypertension (high blood pressure).[1] It contains telmisartan, an angiotensin II receptor blocker; amlodipine, as the besilate salt, a dihydropyridine calcium channel blocker; and indapamide, a thiazide-like diuretic.[1][2]
The combination telmisartan/amlodipine/indapamide was approved for medical use in the United States in June 2025.[1]
Medical uses
Telmisartan/amlodipine/indapamide is indicated for the treatment of hypertension.[1]
Society and culture
Legal status
The combination telmisartan/amlodipine/indapamide was approved for medical use in the United States in June 2025.[1]
References
- ^ a b c d e f "Widaplik (telmisartan, amlodipine and indapamide) tablets, for oral use" (PDF). George Medicines. 2025. Retrieved 9 June 2025.
- ^ Satheesh GS, Dhurjati R, Salam A, Moran AE, Murphy A, Perel P, et al. (2025). Triple fixed-dose combination antihypertensive therapy (PDF) (Report). World Health Organization. Retrieved 9 June 2025.
External links
- Clinical trial number NCT04518306 for "Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension (GMRx2_PCT)" at ClinicalTrials.gov
- Clinical trial number NCT04518293 for "Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension (GMRx2_ACT)" at ClinicalTrials.gov